Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. OSE Immunotherapeutics
  6. Summary
    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
12/03/2021 12/06/2021 12/07/2021 12/08/2021 12/09/2021 Date
10.48(c) 9.95(c) 10.6(c) 10.24(c) 10.06 Last
173 462 89 833 104 867 42 762 22 534 Volume
-5.59% -5.06% +6.53% -3.40% -1.76% Change
More quotes
Estimated financial data (e)
Sales 2021 16,8 M 19,1 M 19,1 M
Net income 2021 -17,9 M -20,3 M -20,3 M
Net Debt 2021 - - -
P/E ratio 2021 -10,5x
Yield 2021 -
Sales 2022 16,6 M 18,8 M 18,8 M
Net income 2022 -19,0 M -21,5 M -21,5 M
Net cash position 2022 76,1 M 86,1 M 86,1 M
P/E ratio 2022 -10,4x
Yield 2022 -
Capitalization 187 M 212 M 212 M
Capi. / Sales 2021 11,1x
EV / Sales 2022 6,66x
Nbr of Employees 51
Free-Float 63,4%
More Financials
Company
Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the bodyÔÇÖs immunological memory so... 
More about the company
Ratings of OSE Immunotherapeutics
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about OSE IMMUNOTHERAPEUTICS
11/30GLOBAL MARKETS LIVE : Amazon, Microsoft, Volvo, Glencore, Regeneron...
11/30OSE Immunotherapeutics Releases Positive Data For COVID-19 Vaccine Candidate; Shares Up..
MT
11/30OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical De..
AQ
11/30OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical De..
CI
11/18OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
AQ
11/17OSE Immunotherapeutics Presented New Translational Data on Tedopi and Preclinical Data ..
AQ
11/17OSE Immunotherapeutics Enrolls First Patient in Phase 2 Study Of Non-Small Cell Lung Ca..
MT
11/17OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
AQ
11/17OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
CI
11/16OSE Immunotherapeutics Presented New Translational Data on Tedopi« and Preclinical Data..
AQ
11/16OSE Immunotherapeutics Presented New Translational Data on Tedopi? and Preclinical Data..
CI
11/15OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Dataáon CLEC-1..
GL
11/15OSE Immunotherapeutics Presents First Positive Preclinical Efficacy Data on CLEC-1
CI
10/19OSE IMMUNOTHERAPEUTICS : to Present New Preclinical Data atáUpcoming Bispecific Antibody a..
AQ
10/13OSE IMMUNOTHERAPEUTICS : to Host Today a Virtual 'Immuno-Oncology R&D Day'
AQ
More news
News in other languages on OSE IMMUNOTHERAPEUTICS
11/30OSE IMMUNO : premiers signaux prometteurs sur le vaccin Covid
11/30Les valeurs à suivre aujourd'hui à la Bourse de Paris Mardi 30 novembre 2021
11/30Qui croire ?
11/30EN DIRECT DES MARCHES : TotalEnergies, Valneva, LDLC, Amazon, Lundin Energy, Volvo Car, Gl..
11/30OSE IMMUNOTHERAPEUTICS : A suivre aujourd'hui
More news
Analyst Recommendations on OSE IMMUNOTHERAPEUTICS
More recommendations
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,24 €
Average target price 16,52 €
Spread / Average Target 61,3%
EPS Revisions
Managers and Directors
Alexis Peyroles Chief Executive Officer & Director
Anne-Laure Autret-Cornet Chief Financial & Administrative Officer
Dominique Costantini Chairman & Development Director
Nicolas Poirier Chief Scientific Officer & Director
Sophie Brouard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OSE IMMUNOTHERAPEUTICS42.22%212
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169